Donor immune cell infusions for viral infections after stem cell transplant
Part of Infections clinical trials.
This trial studies whether directly infusing donor-made immune cells (virus-fighting T-cells) is safe and feasible in people who still have viral infections after a stem cell transplant. It may help your body control infections from adenovirus, CMV, or EBV when standard antiviral treatments aren’t working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult, age 18 or older
- You have already had an allogeneic hematopoietic stem cell transplant (donor transplant)
- You have a viral infection after transplant that is not responding (adenovirus, CMV, or EBV)
- Your infection needs to meet specific “not improving on treatment” or “can’t take treatment” conditions
- You do not have severe graft-versus-host disease (GVHD) higher than grade 2 at the infusion time
- You are not allergic to iron-dextran or to mouse-made (murine) antibody medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment using specially trained immune cells (virus-specific T-cells) to fight stubborn infections with adenovirus, CMV, or EBV in people with weakened immune systems, such as after a stem cell or organ transplant.
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
This trial tests whether adding specially trained immune cells (CTLs) from a related donor to standard treatment helps clear persistent adenovirus or CMV infections after a stem cell transplant. It may be an option if standard antiviral therapy isn't working or causes serious side effects.
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
This trial tests a personalized immune cell treatment (CMV-specific T cells) for people whose CMV (a common herpes virus) persists or comes back after a stem cell transplant. It may help your immune system better control CMV when standard antiviral medicines aren’t fully working or can’t be used.
This early-phase (Phase 1) study tests an immune cell treatment (R-MVST) to help people whose immune system has been weakened by a past transplant and who keep getting viral infections reactivated or not responding well to standard treatment. It may help your body control viruses like EBV, CMV, adenovirus, or BK virus.
Hear when a new Adenovirus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.